Previous close | 14.34 |
Open | 14.48 |
Bid | 13.50 |
Ask | 16.60 |
Strike | 40.00 |
Expiry date | 2025-12-19 |
Day's range | 14.33 - 14.48 |
Contract range | N/A |
Volume | |
Open interest | 768 |
Stock market investors brace for a big week of earnings and econ as Apple, Amazon, Big Pharma and The Fed all line up to deliver news.
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.